Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIPLE: Intraperitoneal fosfomycin, metronidazole and molgramostim in multi-quadrant peritonitis
2024-520317-49-02Phase 2Authorised
- Sponsor
- Reponex Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary peritonitis and peritonitis comparing Intraperitoneal Repomol + fosfomycin + metronidazole with Intraperitoneal saline placebo (2 arms). Primary endpoint: Clinical failure at postoperative day 28. Planned start Aug 2025; status: authorised.
02
Drugs
molgramostimfosfomycinmetronidazole
03
Conditions
secondary peritonitisperitonitis
Beyond the preview
Go deeper on 2024-520317-49-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520317-49-02.